RT Journal Article
SR Electronic
T1 Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.13.21249262
DO 10.1101/2021.01.13.21249262
A1 Halfon, Philippe
A1 Ansaldi, Christelle
A1 Penaranda, Guillaume
A1 Chiche, Laurent
A1 Dukan, Patrick
A1 Stavris, Chloé
A1 Plauzolles, Anne
A1 Retornaz, Frédérique
A1 Bourliere, Marc
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249262.abstract
AB Background & Aim Liver fibrosis screening in primary care population is a major public health issue. The FIB-4 index is a simple non-invasive fibrosis test combining age, transaminases, platelets count, developed for the diagnosis of advanced fibrosis. The aim of our study was to evaluate the interest of liver fibrosis screening using systematic calculation of FIB-4 in routine blood analysis.Methods Between December 2018 and May 2019, we conducted a prospective screening of liver fibrosis in 134 158 patients during a medical check-up including routine blood analysis. Among these patients, 29 707 had transaminases and platelets counts available and benefited from an automatic calculation of FIB-4. Results were obtained from 21 French clinical laboratories in the Bouches du Rhône region.Results Among the 29 707 patients, 2160 (7.3%) had significant fibrosis (FIB-4>2.67). Individual investigation of patients with FIB-4>2.67 allowed to screen 1267 (1267/2160: 59%) patients who were not managed for any liver disease.Conclusions This work demonstrates the interest of FIB-4 for the screening of liver fibrosis in primary care population. Our study strongly supports this easy-to-implement strategy using a simple Fib-4 measure resulting from the use of available routine test results.Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Clinical Registering Number MR-0314071019 (INDS: French National Institute for Medical Data)Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.indsante.fr/fr/repertoire-public/etude-sous-mr-0314071019 Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Protection des Personnes (CPP) Sud-Mediterranee II - Hopital Sainte Marguerite - Pavillon 9, Marseille, FRANCE (http://www.cpp-sudmed2.fr/) Decision: ExemptionAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available immediately after publication with no end date to researchers who provide a methodologically sound proposal. Requests should be addressed by email to g.penaranda@alphabio.fr.NAFLDnon-alcoholic fatty liver diseaseASTaspartate aminotransferaseELFenhanced liver fibrosisALTalanine aminotransferaseFibroscantransient elastographyT2DType 2 diabetes mellitusNASHnon-alcoholic steatohepatitisHCVhepatic C virus